Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19

23 Mar 2022

Abstract excerpt

. In addition, HPSE blockade with Roneparstat significantly attenuated SARS-CoV-2 S1 protein-induced inflammatory cytokine release from human macrophages through disruption of NF-κB signaling. Together, this study provides a proof of principle for the use of Roneparstat as a dual-targeting therapy for COVID-19 to decrease viral infection and dampen the proinflammatory immune response mediated by macrophages.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to Immune Response and Inflammation
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35319225
DOI: 10.1128/jvi.00057-22

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Heparanase Blockade as a Novel Dual-Targeting Therapy for COVID-19PMID 35319225Read ↗

A vimentin-targeting oral compound with host-directed antiviral and anti-inflammatory actions addresses multiple features of COVID-19 and related diseasesSemantic proximity Read ↗

Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry PerspectiveSemantic proximity Read ↗

DEVELOPING NEW DUAL-ACTION ANTIVIRAL/ANTI-INFLAMMATORY SMALL MOLECULES FOR COVID-19 TREATMENT USING IN SILICO AND IN-VITRO APPROACHESSemantic proximity Read ↗

Small molecules in the treatment of COVID-19Semantic proximity Read ↗

SARS-CoV-2 Envelope protein (E) binds and activates TLR2: A novel target for COVID-19 interventionsSemantic proximity Read ↗

Hypothesis: Alpha-1-antitrypsin is a promising treatment option for COVID-19Semantic proximity Read ↗

Targeting conserved regions of the SARS-CoV-2 polymerase (RdRp) with kinase inhibitors as an effective new tactic for discovering dual-action "antiviral–antiinflammatory" drugs against COVID-19Semantic proximity Read ↗

Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in severe COVID-19Semantic proximity Read ↗

Efficacy of Host Cell Serine Protease Inhibitor MM3122 against SARS-CoV-2 for Treatment and Prevention of COVID-19Semantic proximity Read ↗

Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19Semantic proximity Read ↗

Brilacidin, a COVID‐19 drug candidate, demonstrates broad‐spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cellSemantic proximity Read ↗

Papaverine targets STAT signaling: a dual-action therapy option against SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.